Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy
Status:
Unknown status
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis in the
world.There is to date no curative therapy for patients with IgAN.It is considered that
dendritic cells, Toll-like receptor (TLR) 9 and cytokines interleukin-6 (IL-6), and
interferon-alpha (IFN-a) and tumor necrosis factor-alpha (TNF-α), play an important role in
the aberrant mucosal response. Hydroxychloroquine is an antimalarial agent and had a notable
impact on immune activation by the reduction of circulating activated immune cells that
including decreased TLR-expressing cells, reduced IFN-secreting plasmacytoid dendritic cells,
reduced production of inflammatory cytokines including interferon alpha, IL-6 and TNF alpha.
Recent studies showed hydroxychloroquine had a benefit for renal remission and could retard
the onset of renal damage in patients with lupus nephritis. hydroxychloroquine may have the
potential effect in IgA nephropathy, alleviated the proteinuria and had the renal protect
effect. This will be a single center, prospective, randomized, controlled study to assess the
utility of hydroxychloroquine in IgAN patients.
Phase:
Phase 4
Details
Lead Sponsor:
Peking Union Medical College Hospital
Treatments:
Hydroxychloroquine Molecular Mechanisms of Pharmacological Action Valsartan